Bayer (BAYN) Price & Analysis

Compare

801 Followers

BAYN Stock Chart & Stats

€33.30

€0.08(0.41%)

At close: Jan 09 4:00 PM EST

€33.30

€0.08(0.41%)

Day’s Range― - ―

52-Week Range€18.38 - €35.02

Previous CloseN/A

Volume533.42K

Average Volume (3M)2.24M

Market Cap

€26.28B

Enterprise Value€59.09B

Total Cash (Recent Filing)€5.50B

Total Debt (Recent Filing)€38.43B

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Mar 03, 2026

EPS Estimate

0.32

Last Dividend Ex-Date

Apr 28, 2025

Dividend Yield0.33%

Share Statistics

EPS (TTM)0.57

Shares Outstanding982,424,100

10 Day Avg. Volume2,239,372

30 Day Avg. Volume2,240,598

Financial Highlights & Ratios

PEG Ratio0.57

Price to Book (P/B)0.59

Price to Sales (P/S)0.41

P/FCF Ratio4.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€31.26

Price Target Upside-6.13% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering12

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash Flow MeasuresThe company has implemented measures to maximize cash flow generation, which is crucial given the high level of debt.

Debt ReductionNet debt at €32.6bn (FY-23: 34.5bn), which is good news.

Bears Say

Agrochemicals PerformanceBayer underperformed significantly due to weaker-than-expected agrochemicals performance and questions on long-term pharma growth.

EBITDA DeclineQ4 clean EBITDA came in at EUR 2.35bn, which is materially down y/y (-22% y/y, Stifel: €2.24bn, consensus: €2.1bn).

Generics ImpactThe Crop Science business is facing a broader-than-expected generics impact, affecting the company's overall performance.

Litigation UncertaintyOngoing litigation related to glyphosate is creating uncertainty for investors, with 67,000 cases still unsettled.

Bayer News

Bayer upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Bayer (BAYRY) to Overweight from Neutral with a price target of EUR 50, up from EUR...

4h ago

Bayer initiates clinical trial with BAY 3401016

Bayer (BAYRY) announced initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with...

4d ago

Bayer says Gadoquatrane met primary, secondary endpoints in trial

Bayer (BAYRY) announced results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of...

5d ago

Bayer upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin upgraded Bayer (BAYRY) to Overweight from Equal Weight with a price target of...

5d ago

Bayer welcomes Solicitor General support for U.S. Supreme Court review

Bayer (BAYRY) said it is “pleased the Solicitor General supports U. S. Supreme Court review of the petition...

6d ago

Bayer starts SUNFLOWER study

Bayer (BAYRY) announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and...

6d ago

Bayer announces MEDRAD Centargo system secures 510(k) clearance

Bayer (BAYRY) announced that its MEDRAD Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food...

7d ago

Dare Bioscience announces return of rights to Oveprene

Dare Bioscience (DARE) announced that all rights to Ovaprene, the company’s first-in-category, investigational, hormone-free monthly intravaginal contraceptive, will...

7d ago

DARE

Bayer data could ‘somewhat renew’ optimism for Bristol drug, says Morgan Stanley

Morgan Stanley analyst Terence Flynn notes that Bayer (BAYRY) reported positive top line data from a Phase 3...

14d ago

BMY

Video: Biogen up after Novo weight-loss drug fails to slow Alzheimer’s progress

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

14d ago

BMY

Bayer AG Announces Upcoming Financial Report Releases

The latest announcement is out from Bayer ( ($DE:BAYN) ). Bayer Aktiengesellschaft has announced the upcoming disclosure of...

21d ago

0P6S Upcoming Earnings Report: What to Expect?

Bayer Ag (UK) (0P6S) is scheduled to report 3rd quarter earnings on 11/12/2025, before the market opens. Regarding...

28d ago

Bayer AG’s New Pediatric Study: A Closer Look at Rivaroxaban for VTE

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

4M ago

Bayer AG’s Promising Phase 3 Study on Prostate Cancer Treatment

Bayer AG (($BAYRY)), Bayer Ag (UK) (($GB:0P6S)) announced an update on their ongoing clinical study. Study Overview: Bayer...

4M ago

BAYN FAQ

What was Bayer’s price range in the past 12 months?

Bayer lowest stock price was €18.38 and its highest was €35.02 in the past 12 months.

What is Bayer’s market cap?

Bayer’s market cap is €26.28B.

When is Bayer’s upcoming earnings report date?

Bayer’s upcoming earnings report date is Mar 03, 2026 which is in 85 days.

How were Bayer’s earnings last quarter?

Bayer released its earnings results on Nov 12, 2025. The company reported €0.57 earnings per share for the quarter, beating the consensus estimate of €0.366 by €0.204.

Is Bayer overvalued?

According to Wall Street analysts Bayer’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bayer pay dividends?

Bayer pays a Annually dividend of €0.11 which represents an annual dividend yield of 0.33%. See more information on Bayer dividends here

What is Bayer’s EPS estimate?

Bayer’s EPS estimate is 0.32.

How many shares outstanding does Bayer have?

Bayer has 982,424,100 shares outstanding.

What happened to Bayer’s price movement after its last earnings report?

Bayer reported an EPS of €0.57 in its last earnings report, beating expectations of €0.366. Following the earnings report the stock price went up 5.942%.

Which hedge fund is a major shareholder of Bayer?

Currently, no hedge funds are holding shares in DE:BAYN

Bayer Stock Smart Score

Outperform

Fundamentals

Return on Equity

-0.66%

Trailing 12-Months

Asset Growth

-12.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bayer

Bayer AG is a global life sciences company headquartered in Leverkusen, Germany, with a rich history that dates back to 1863. It operates primarily in three main sectors: Pharmaceuticals, Consumer Health, and Crop Science. Bayer's Pharmaceuticals division focuses on prescription products in areas such as cardiology, oncology, and women's health. The Consumer Health division offers over-the-counter products including pain relievers, dietary supplements, and dermatological solutions. The Crop Science sector provides innovative agricultural solutions, including crop protection, seeds, and digital farming technologies, aimed at enhancing agricultural productivity and sustainability.

Bayer (BAYN) Earnings & Revenues

Historic Earnings Reports

BAYN Stock 12 Month Forecast

Average Price Target

€31.26

▼(-6.13% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","41":"€41","23.75":"€23.8","29.5":"€29.5","35.25":"€35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€31.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,23.75,29.5,35.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.47,31.20307692307692,31.936153846153847,32.669230769230765,33.402307692307694,34.135384615384616,34.86846153846154,35.60153846153846,36.33461538461538,37.067692307692305,37.800769230769234,38.533846153846156,39.26692307692308,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.47,30.53076923076923,30.591538461538462,30.65230769230769,30.713076923076922,30.773846153846154,30.834615384615386,30.895384615384614,30.956153846153846,31.016923076923078,31.07769230769231,31.138461538461538,31.19923076923077,{"y":31.26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.47,29.895384615384614,29.32076923076923,28.746153846153845,28.17153846153846,27.596923076923076,27.02230769230769,26.447692307692307,25.873076923076923,25.298461538461538,24.723846153846154,24.14923076923077,23.574615384615385,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.193,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.221,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.536,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.601,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.208,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >